The Neurodevelopmental Consequences of Congenital Heart Disease

By Gil Wernovsky, MD; Mary T. Donofrio, MD; Melissa B. Jones, MSN, CPNP-AC; Jacqueline Sanz, PhD, ABPP-CN

Background

Children with complex Congenital Heart Defects (cCHD) are now surviving neonatal and infant surgery with a frequency thought to be impossible only a generation ago. While advances in Medicine and Surgery have allowed the ability to “mend” children born with CHD, the increasing number of survivors has created a growing population of children in our primary and secondary school systems, and young adults entering the job force. In the United States alone, over 35,000 infants are born each year with CHD, and more than a third of these infants have cCHD, and will undergo “palliative” or “corrective” surgical interventions in the first year of life. It is estimated that there are more than one million adults now living in the USA with a variety of CHDs, which includes over 150,000 adults living with cCHD. Due to improved survival rates in the past two decades, there are larger numbers of school-age children with increasingly complex forms of CHD. As survival rates have increased, additional attention has been directed toward understanding and treating the long-term challenges for these children and young adults, including behavioral problems, academic performance and mood disorders, all of which combine to affect health-related quality of life.

The “Neurodevelopmental Phenotype” in cCHD (see Table)

As a group, children and young adults with cCHD have a higher likelihood of academic, behavioral, social-emotional and motor coordination problems compared to children without CHD. While not all children with cCHD have these difficulties, the percentage of children with these challenges is significantly higher than in the general population. These problems are more prevalent in children with cCHD compared to less severe forms of CHD that do not require surgery, can be treated during catheterization, or do not require surgery until later childhood (see Figure).

Infancy

In infancy, problems that are more prevalent include feeding difficulties (perhaps in half of all children requiring heart surgery as neonates) and delays in reaching some important motor milestones such as rolling over, crawling or walking – opportunities for them to explore the environment. Although most neonates achieve full feedings by mouth shortly after discharge from the hospital, many require supplemental tube feedings into later infancy and beyond. While delays in motor
NOW ENROLLING:

Harmony™ Transcatheter Pulmonary Valve (TPV) Clinical Study

WHAT IS THE MEDTRONIC HARMONY TPV CLINICAL STUDY?
The study is a multi-center prospective, non-randomized, interventional pre-market study in the United States. The purpose of the study is to evaluate the safety and effectiveness of the Harmony TPV system in patients who have congenital heart disease and are clinically indicated for pulmonary valve replacement. The trial will involve up to 40 subjects implanted at 10 study centers.

WHO CAN PARTICIPATE?
Patients who have pulmonary regurgitation:
- Severe pulmonary regurgitation by echocardiography, or
- Pulmonary regurgitant fraction ≥ 30% by cardiac magnetic resonance imaging

Patients who have a clinical indication for surgical placement of a RV-PA conduit or prosthetic pulmonary valve:
- Subject is symptomatic secondary to pulmonary insufficiency (e.g., exercise intolerance, fluid overload), or
- Right ventricular end diastolic volume index ≥ 150 mL/m², or
- Subject has RVEDV:LVEDV Ratio ≥ 2.0

HOW CAN I LEARN MORE ABOUT THE HARMONY TPV CLINICAL STUDY?
For additional information about the program, please contact Medtronic at:
RS.HarmonyTPVClinicalStudy@medtronic.com

CAUTION: Investigational Device. Limited by Federal Law (USA) to Investigational Use.
skills are extremely common, most of the infant’s milestones are delayed by only a few months or so. Following heart surgery in the neonate and infant, many heart centers now perform speech, occupational and physical therapy evaluations and treatment, as well as long-term follow-up – as recommended by the American Heart Association and American Academy of Pediatrics.

Preschool

In preschool, there is a growing recognition of delays in certain elements of speech and language. To greatly oversimplify, speech and language can be broken down into two components: receptive language (the child hears and understands words), and expressive language (using words and sentences to communicate effectively). In many children with cCHD, receptive language is normal (e.g., if you say “point to the apple”, the child will point to the apple). In contrast, children may have trouble with articulation (or coordinating the oral movement needed for forming words correctly), and with more complex expressive language. For example, a child may have trouble finding the right words (e.g., when you point to an apple and say, “what is that?”), even though the child knows it’s an apple), or as they get older, they may have trouble organizing sentences, staying on topic, or following the flow of a conversation. Importantly, recent work has suggested that up to 25% of children with cCHD have some form of hearing loss after surgery, which substantially impacts the development of language and academic skills; a formal hearing evaluation should be considered as part of the routine follow-up of these children.

In addition to delays in expressive language, some preschool children with cCHD (at least 25%) have ongoing difficulties with motor skills, including large motor delays (clumsiness), fine motor delays (problems with buttoning, zipping, cutting), and visual-motor delays (drawing). Visual-motor integration relates to the ability to coordinate thoughts and images into motor action. In preschool and school age children, handwriting represents a particular challenge: seeing handwriting on the board, knowing that it’s a particular letter, and getting the hand to make the letter can be very frustrating to an otherwise bright child. In many children, fine and gross motor skills improve by the time they enter school, though visual-motor problems remain prevalent.

By preschool age, problems with executive skills also begin to emerge. Executive function (EF) refers to a group of skills used to complete novel or complex tasks. In other words, these are not the “know how,” but the “how you do it” skills, and become more important when we need to tackle something new or different – when we aren’t on auto-pilot. Core components of EF include inhibition (being able to “put on the brakes” when needed), working memory (our mental chalkboard, where we keep track of and work with information “in our head”), and flexibility (being able to generate multiple solutions, change tactics when needed, and transition effectively between tasks/activities). These core skills allow us to initiate, plan, and organize our approach to tasks, and to regulate our
emotions and behaviors across situations. For example, preschoolers with cCHD may have difficulty with tantrums, transitions, following classroom routines, or remaining flexible in social situations.

**School-Age and Beyond**

As children with cCHD enter primary and secondary school in larger numbers, there is a growing recognition of a combination of challenges that may combine to cause academic and social problems. As we look more carefully at children with cCHD, there is a higher rate of diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), with estimates ranging between 25%-53% of children showing symptoms of the disorder, compared to 7-10% of the general population. The core features of ADHD include problems with attention, hyperactivity, and impulsivity, along with executive dysfunction. There are also higher rates of learning disabilities and academic problems in children with cCHD.

Early delays in language, visual and motor skills, processing speed, and self-regulation may interact over time to contribute to increased rates of ADHD and learning disorders, and problems in school more generally. Problems with EF are of particular interest, as they are one of the more commonly reported concerns in children, adolescents, and adults with cCHD (with studies consistently finding that more than half of these children have concerns around some aspects of EF). EF is also known to strongly predict success in school (more so than “IQ” or early academic skills) and social relationships, and to strongly influence mental health and quality of life. That is, a child or teen with poorly developed EF may be bright and a strong reader, but struggle with tying together broader themes or “main ideas” when reading, or may have trouble effectively communicating while writing. They may master early math but have trouble with more complex math problem solving. They can struggle to complete work on time, procrastinate (since they have trouble knowing where to start), or forget to turn in completed work. This can lead to frustration as children, adolescents, and adults often fail to truly demonstrate otherwise strong skills in school or at work.

Finally, there are social-emotional challenges. Many children with cCHD have weaknesses with social skills and higher order language. There is an increased incidence of Autism, which is characterized by problems with social skills, communication, and flexibility. Problems with mood and anxiety are also common starting in school age, adolescence, and adulthood.

Despite these risks, there are many children with cCHD, even those with very complex medical histories, who do exceedingly well and do not seem to experience these challenges. It is important for us to investigate the “protective” factors from these individuals – in other words, what provides “resiliency” in the face of cCHD? In addition, there are many effective forms of intervention for ADHD, executive dysfunction, and learning disorders, and these can very much improve outcomes, especially when implemented early, though it should also be stated that it’s never too late. Parents and providers should also work to identify and cultivate each child’s strengths and talents, and to figure out how their child learns best. Because of this, the AHA and AAP recognize the importance of regular neurodevelopmental evaluations in this high-risk sample, so that problems can be identified and managed early.

**Etiology**

Although it is tempting to point at “one” feature as “the cause” of the above findings seen so commonly in cCHD, that would be a terrible oversimplification. The effects of cCHD on the developing brain of children are multiple, and cumulative over the early years of development.

Following conception, the closure of the neural tube and early brain development occurs at the same time that the heart forms, in the first trimester. In most cases, whatever causes CHD has “left its mark” on the heart by the end of the 8th week of gestation. In contrast, the brain continues to develop and mature throughout pregnancy (and beyond). Studies are accumulating, demonstrating that the abnormal circulation caused by cCHD in the fetus is likely responsible for some of the abnormalities in brain growth and development present at birth. Clearly, “congenital heart disease” and “congenital brain disease” are co-linked variables in many children. Does the same factor or factors that cause CHD also cause brain abnormalities as well? Is the brain “wired” the same way in children with CHD compared to normal? How does the abnormal fetal circulation put an abnormal fetal brain at greater risk for other stressors? Early work in this area was limited to post-natal findings such as microcephaly and neonatal neurological examinations. Subsequent work utilizing fetal Doppler ultrasound revealed abnormalities in cerebral vascular pulsatility suggesting cerebral vasoconstriction and a decrease in cerebral vascular resistance in left heart obstructive lesions, with some suggesting an elevation in cerebral vascular resistance in right-sided lesions. However, now that newer technologies such as Magnetic Resonance Imaging (MRI) in the fetus and newborn have become more routinely available, it has been noted that there is a mismatch of oxygen and likely substrate (glucose) delivery to the highly metabolically active brain of the developing fetus, particularly in the third trimester. Exciting developments in the understanding of placental development and altered placental function are on the horizon as well. The brain of many newborns with cCHD delivered at term appears ‘immature’; several studies have shown that the brain of a full-term infant with cCHD has the complexity (or “maturity”) of the brain of a 35-36 week gestation infant without cCHD. This has led to a paradigm shift over the past decade to encourage delivery as close to term (39-40 weeks) as possible, unless there are maternal or fetal reasons to recommend earlier delivery. Finally, genome-wide analyses and certain polymorphisms are being linked to both the prevalence of later school difficulties and cCHD, and also in the way the brain of the newborn responds to stressors such as cardiopulmonary bypass and postoperative care.

Importantly, many published studies exclude children with other known conditions which affect neurodevelopment, such as genetic syndromes, prematurity and additional congenital anomalies. Genetic syndromes and abnormalities on genetic screening, and/or additional congenital anomalies exist in up to 25% of neonates with cCHD. Finally, population studies of newborns with cCHD suggest a higher incidence of prematurity and “small for gestational age,” possibly suggesting a role of placental insufficiency. The placenta may be inherently abnormal and low fetal cardiac output and oxygen delivery to the placental circulation may be a factor, again suggesting an interaction between the type of cCHD and its effect on oxygen delivery and cardiac output to the fetal-placental axis.

For neonates with cCHD after birth, multiple factors occur nearly simultaneously that make it extremely difficult to separate out their relative contributions to long-term outcomes. These factors include, but are not limited to: hypoxemia, low cardiac output, cardiopulmonary bypass, analgesic and anxiolytic medications, volatile anesthetic agents, paradoxical emboli (in children with right-to-left shunting), nutritional deficiencies, limited mobility and developmental stimulation in the early postoperative period, noise exposure, plastics and other toxins, prolonged mechanical ventilation and many more. In essentially all published studies, longer hospital Length of Stay (LOS) is related to worse long-term outcomes. It is highly likely that longer LOS represents a surrogate outcome variable for the additive and interactive causes mentioned above. Finally, the combined effects of a long stay in the intensive care unit and hospital on both the baby and the family, greatly increase the risk of Acute- and Post-Traumatic Stress Disorder in parents (see below).

In past research, many long-term neurodevelopmental findings were attributed to cardiopulmonary bypass (CPB, particularly its duration), pH management, deep hypothermic circulatory arrest, hematocrit, temperature, steroid use, modified ultrafiltration, and more. While these factors are certainly important to the brain and later development, recent work suggests that these effects are seen early in life, but
become minimal as the children develop. In the Boston Circulatory Arrest Study, the longest prospectively published study to date, deep hypothermic circulatory arrest (DCHA) was related to abnormal outcomes through age four, both DHCA and low flow CPB were each related to different types of abnormalities at age eight, and by age 16, none of the measured CPB variables had a significant effect on outcomes. Importantly, in many studies, CPB and intraoperative management are responsible for less than 5% of the variability of long-term developmental outcomes. Perhaps the most important factor in cardiac surgery and recovery is the technical success of the operation. An anatomically and physiologically successful operation leads to improved postoperative oxygen delivery and a shorter length of stay in the hospital; we believe that this is more important than how long it takes to accomplish the operation or factors related to CPB.

Treatment

Thus far, research in the treatment of neurodevelopmental problems in patients with cCHD lags behind research in prevalence and etiology. For example, there is limited data at the current time to comment on the safety and efficacy of the psychotropic drugs (for example, stimulant medications for ADHD, anti-depressants, etc.) in children with cCHD, and this must be an individual decision with a child’s cardiologist. Many of the medications currently available for children with structurally normal hearts slightly increase the risk of rhythm problems and high blood pressure; and some children with CHD may be at increased risk for rhythm disturbances when using these medications. It must be emphasized that no large study has determined the safety and efficacy of these drugs specifically in children with cCHD, or even if they work the same way as in children with structurally normal hearts. The decision to use medications to deal with behavioral issues or ADHD must be individualized to the child, balancing the unknown risks of these medications in children with CHD against the lifelong implications of academic and social difficulties. Close follow-up, planning and surveillance are warranted when beginning any new medication. Whether or not medication is used as a treatment tool, parents and families should be encouraged to seek out evidence-based therapies to treat speech-language and motor delays, executive dysfunction, and learning differences. Most often, it is the combination of medical and behavioral/therapeutic approaches that is most effective. Harnessing community resources, such as services and supports in the school system (e.g., individualized educational plans) is also critically important. Finally, one must address post-traumatic medical stress and family functioning, and evidence-based therapy for mood or anxiety disorders. Most researchers agree that this is a central component to increasing effectiveness of other interventions.

Some studies are underway investigating whether increasing oxygen delivery to the brain and/or placenta of a fetus with cCHD can be safely accomplished through maternal administration. Also, there is growing evidence in studies across the globe that treatments geared toward decreasing maternal worry and improving parental mental health show significant promise in improving long-term outcomes. These include prenatal counseling, pre- and post-operative support with clergy and palliative care teams, and increased contact with advanced practice nurses prior to and after hospital discharge.

Future Directions

In our opinion, the outlook for children with cCHD remains quite optimistic. Many are now adults and are engineers, nurses, doctors, social workers, and teachers; many are parents themselves, and lead happy, productive lives. Nonetheless, there are ongoing challenges for those of us who care for these children to improve overall quality of life. It is important to emphasize that long-term prospective studies, and cross-sectional studies in older adults with CHD represent management strategies from the 1970’s-2000’s, and there is a suggestion that there is some improvement in many areas of functioning for children born more recently. This is likely due to the many important and simultaneous improvements in the last two decades— including more frequent prenatal diagnosis, research into the developing brain before and after surgery, a better understanding of anesthesia and cardiopulmonary bypass, improved post-operative care, and the benefits of structured follow-up programs. A number of additional factors will ultimately contribute to the academic success of our children, including genomics and a personalized medicine approach to surgery and perioperative care.

It has also been learned that - not surprisingly - the stress of having a child with cCHD on parents and families is prevalent, occasionally severe and long-lasting. Importantly, taking steps to improve parental mental health (mindfulness techniques, PTSD therapy, etc.) improve both the parents and the child’s long-term outlook. As is said when you board an airplane: “Put your own mask on first before helping others”. We cannot over-emphasize the importance of self-care – both physically and mentally – for families affected by a child with cCHD.

Finally, the best way to improve the outcomes for future generations is a continued and long-term partnership between patients, parents, researchers, nurses, therapists, psychologists, physicians and many others. Advocacy by physicians, parents and patients at the government level for continued funding of research is crucial. We must continue to pursue the causes and treatment of heart disease in children, as well as the secondary effects on the brain and quality of life. Philanthropic contributions play a significant role in start-up funds for research as well. Finally, if families and children are willing, voluntary participation in clinical research studies remains the cornerstone of the process.

Summary of Current Findings, 2018

- In the absence of an associated structural brain abnormality or genetic syndrome, cognitive function (IQ, intelligence) is typically within the normal range for most children with CHD.
- Parental education, mental health and socioeconomic status are consistently the most strongly associated factors in the long-term outcomes for children with cCHD, rather than the specific type of CHD or its management. Of these, while the effects of low socioeconomic status may be attenuated by participation in enrichment programs (e.g., early preschool, “headstart”), only parental mental health is truly modifiable.
- Early delays with language, motor, and visual motor skills are common in children with cCHD.
- Problems with executive function – which affects behavioral regulation and completion of complex tasks – are highly prevalent in cCHD, and may be the most important factor in long term success and health-related quality of life.
- There are higher rates of ADHD, learning disorders, and autism in children with cCHD.
- Some identified risk factors for academic and behavioral difficulties include highly complex CHD requiring multiple procedures, a long hospital stay, and family PTSD. Health-related quality of life is also affected by the number of medications necessary and number of doctor visits per year.
- The association between abnormal fetal oxygen and substrate delivery, open heart surgery and postoperative care with later cognitive, language, or behavior difficulties continues to be an active area of investigation.

Given these findings, The American Heart Association and American Academy of Pediatrics have recommended regular neurodevelopmental evaluations, in infancy, school age, and adolescence, for children with cCHD. Included below is a list of recent selected interdisciplinary references related to the diagnosis and treatment of neurodevelopmental disabilities in children with cCHD.

To learn more, please join us at the 7th Scientific Sessions of the Cardiac Neurodevelopmental Outcome Collaborative, June 6-8, 2018 in Kansas City, USA. See http://bit.ly/CNOC18 for more details.
References

1. Aly (2016); Cerebral tissue oxygenation index and lactate at 24 hours postoperative predict survival and neurodevelopmental outcome after neonatal cardiac surgery. Congenital Heart Disease, 12, 188-195.

2. Andescavage (2015); 3-D volumetric MRI evaluation of the placenta in fetuses with complex congenital heart disease. Placenta, 36; 1024-1030.


13. Calderon (2015); Executive function deficits in congenital heart disease: why is intervention important? Cardiology in the Young 25, 1238-1246.


23. Fantasia (2018); Fetal major cardiac defects and placental dysfunction at 11–13 weeks' gestation. Ultrasound in Obstetrics and Gynecology 51, 194-198.


27. Greenberg (2017); High burden of genetic conditions diagnosed in a cardiac neurodevelopmental clinic. Cardiology in the Young, 27, 459-466.


35. Kaugars (2018); Stress and quality of life among parents of children with congenital heart disease referred for psychological services. Congenital Heart Disease 13, 72-78.

36. Kelly (2017); Impaired development of the cerebral cortex in infants with congenital heart disease is correlated to reduced cerebral oxygen delivery, Scientific Reports 7, 15088.


38. Ladouceur (2017); Educational needs of adolescents with congenital heart disease: Impact of a transition intervention programme. Archives of Cardiovascular Disease, 110, 317-324.


40. Limperopoulos (2010); Brain volume and metabolism in fetuses with congenital heart disease: Evaluation with quantitative magnetic resonance imaging and spectroscopy. Circulation 121, 26–33.

41. Locchoh (2018); Prevalence and risk factors associated with non-attendance in neurodevelopmental follow-up clinic among infants with CHD. Cardiology in the Young, 28, 5560.


43. Matthiesen (2016); Congenital Heart Defects and Indices of Fetal Cerebral Growth in a Nationwide Cohort of 924422 Liveborn Infants. Circulation 133:566-575.


45. Marino (2012); Neurodevelopmental outcomes in children with congenital heart

47. McCusker (2010); A controlled trial of early interventions to promote maternal adjustment and development in infants born with severe congenital heart disease. Child: Care, Health and Development. 36,110-117.


51. McKean (2017); Feeding difficulties in neonates following cardiac surgery: Determinants of prolonged feeding-tube use. Cardiology in the Young 27:1203.


59. Rollins (2017); Genetic contribution to neurodevelopmental outcomes in congenital heart disease: are some patients predetermined to have developmental delay? Current Opinion in Pediatrics, 29, 529-33.

60. Russell (2018); Advances in the understanding of the genetic determinants of congenital heart disease and their impact on clinical outcomes. Journal of the American Heart Association 7, e006906.


63. Schmithorst (2016); Organizational topology of brain and its relationship to ADHD in adolescents with d-transposition of the great arteries. Brain and Behavior, 6, e0054.


Children with complex Congenital Heart Defects (cCHDs) are now surviving neonatal and infant surgery with a frequency thought to be impossible only a generation ago. While advances in Medicine and Surgery have allowed the ability to “mend” children born with CHD, the increasing number of survivors has created a growing population of children in our primary and secondary school systems, and young adults entering the job force.”


77. Corresponding Author
Gil Wernovsky, MD, FAAP, FACC
Senior Consultant in Cardiac Critical Care and Pediatric Cardiology
Children’s National Medical Center
111 Michigan Ave. NW
Washington, DC 20010 USA
gwernovsky@childrensnational.org

Mary T. Donofrio, MD, FAAP, FACC, FASE
Professor of Pediatrics
George Washington University
Director of the Fetal Heart Program
Children’s National Heart Institute Cardiac Neurodevelopmental Outcome Program
Children’s National Medical Center
111 Michigan Ave. NW
Washington, DC 20010 USA

Jacqueline Sanz, PhD, ABPP-CN
Clinical Neuropsychologist
Children’s National Heart Institute Cardiac Neurodevelopmental Outcome Program
Children’s National Medical Center
111 Michigan Ave. NW
Washington, DC 20010 USA

CCT

The congenital heart professionals network exists to facilitate communications between congenital heart professionals locally, regionally, and globally.
With the 2018 “Specialty Review in Pediatric Cardiology Course” approaching, I am thinking back to its beginning. Even though pediatric cardiology in the seventies was rapidly expanding in diagnostic and surgical techniques, candidates for board examination had to rely on repeated visits to the medical library to update their knowledge and refresh the experience acquired during their training. A preparatory curriculum was clearly needed.

Starting in 1976 I organized the first “Specialty Review in Pediatric Cardiology” run under the auspices of the Cook County Graduate School of Medicine of Chicago, with faculty drawn from local universities. That year the program was two days in length and was attended by approximately 30 registrants from throughout the United States.

Over the years the course expanded to its present 5-day format, attracting attendees not only from the US but from abroad as well, with a distinguished national planning committee and faculty.

“Over the years the course expanded to its present 5-day format, attracting attendees not only from the US but from abroad as well, with a distinguished national planning committee and faculty. Perhaps the most important recognition to the quality and continuing relevance of the course came in 2010 when sponsorship was assumed by the American Academy of Pediatrics Section on Cardiology and Cardiac Surgery in collaboration with the Society of Pediatric Cardiology Training Program Directors.”

**CONGENITAL CARDIOLOGY TODAY**

CALL FOR CASES AND OTHER ORIGINAL ARTICLES

Do you have interesting research results, observations, human interest stories, reports of meetings, etc. to share? Submit your manuscript to: RichardK@CCT.bz
RIGHT CHOICE.

Melody™ Transcatheter Pulmonary Valve (TPV) System

Restoring lives for 11 years and counting.

The only transcatheter pulmonary valve specifically designed for RVOT conduits and bioprosthetic valves. The longest studied, with the largest body of clinical evidence at 7 years post-implant. Over 11 years of implants, more than 12,000 patient lives have been changed.

Melody TPV — The Right Choice for Your Patients

*Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Original OCT Clinical Data. ©2022 Medtronic. All rights reserved.*

Medtronic Further. Together

RIGHT DESIGN.

Melody™ Transcatheter Pulmonary Valve (TPV) System

Confident with over 7 years of clinical data.

The only transcatheter valve designed specifically for RVOT conduits and bioprosthetic valves. Thin leaflets from naturally derived tissue open and close under minimal pressure. The flexible delivery system is designed for the right side of the heart and offers controlled, stepwise deployment of the valve with balloon-in-balloon technology.

Melody TPV — The Right Design for Your Patients

*Melody Transcatheter Pulmonary Valve Study: Post Approval Study of the Original OCT Clinical Data. ©2022 Medtronic. All rights reserved.**
Melody™ Transcatheter Pulmonary Valve, Ensemble™ II Transcatheter Valve Delivery System

Important Labeling Information for the United States

Indications: The Melody TPV is indicated for use in the management of pediatric and adult patients who have a clinical indication for intervention on a dysfunctional right ventricular outflow tract (RVOT) conduit or surgical bioprosthetic pulmonary valve that has ≥ moderate regurgitation, and/or a mean RVOT gradient ≥ 35 mm Hg.

Contraindications: None known.

Warnings/Precautions/Side Effects:

- DO NOT implant in the aortic or mitral position. Pre-clinical bench testing of the Melody valve suggests that valve function and durability will be extremely limited when used in these locations.
- DO NOT use if patient’s anatomy precludes introduction of the valve, if the venous anatomy cannot accommodate a 22 Fr size introducer, or if there is significant obstruction of the central veins.
- DO NOT use if there are clinical or biological signs of infection including active endocarditis. Standard medical and surgical care should be strongly considered in these circumstances.

- Assessment of the coronary artery anatomy for the risk of coronary artery compression should be performed in all patients prior to deployment of the TPV.
- To minimize the risk of conduit rupture, do not use a balloon with a diameter greater than 110% of the nominal diameter (original implant size) of the conduit for pre-dilation of the intended site of deployment, or for deployment of the TPV.

The potential for stent fracture should be considered in all patients who undergo TPV placement. Radiographic assessment of the stent with chest radiography or fluoroscopy should be included in the routine postoperative evaluation of patients who receive a TPV.

- If a stent fracture is detected, continued monitoring of the stent should be performed in conjunction with clinically appropriate hemodynamic assessment. In patients with stent fracture and significant associated RVOT obstruction or regurgitation, reintervention should be considered in accordance with usual clinical practice.

Potential procedural complications that may result from implantation of the Melody device include the following: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, pain, swelling or bruising at the catheterization site.

Potential device-related adverse events that may occur following device implantation include the following: stent fracture, stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, hemolysis.

For additional information, please refer to the Instructions for Use provided with the product or available on http://manuals.medtronic.com.

Important Labeling Information for Geographies Outside of the United States

Indications: The Melody™ TPV is indicated for use in patients with the following clinical conditions:

- Patients with regurgitant prosthetic right ventricular outflow tract (RVOT) conduits or bioprostheses with a clinical indication for invasive or surgical intervention, OR
- Patients with stenotic prosthetic RVOT conduits or bioprostheses where the risk of worsening regurgitation is a relative contraindication to balloon dilation or stenting

Contraindications:

- Venous anatomy unable to accommodate a 22 Fr size introducer sheath
- Implantation of the TPV in the left heart
- RVOT unfavorable for good stent anchorage
- Severe RVOT obstruction, which cannot be dilated by balloon
- Obstruction of the central veins
- Clinical or biological signs of infection
- Active endocarditis
- Known allergy to aspirin or heparin
- Pregnancy

Potential Complications/Adverse Events: Potential procedural complications that may result from implantation of the Melody device include the following: rupture of the RVOT conduit, compression of a coronary artery, perforation of a major blood vessel, embolization or migration of the device, perforation of a heart chamber, arrhythmias, allergic reaction to contrast media, cerebrovascular events (TIA, CVA), infection/sepsis, fever, hematoma, radiation-induced erythema, pain, swelling or bruising at the catheterization site.

Potential device-related adverse events that may occur following device implantation include the following: stent fracture, stent fracture resulting in recurrent obstruction, endocarditis, embolization or migration of the device, valvular dysfunction (stenosis or regurgitation), paravalvular leak, valvular thrombosis, pulmonary thromboembolism, hemolysis.

The Melody Transcatheter Pulmonary Valve and Ensemble II Transcatheter Delivery System has received CE Mark approval and is available for distribution in Europe.
Perhaps the most important recognition to the quality and continuing relevance of the course came in 2010 when sponsorship was assumed by the American Academy of Pediatrics Section on Cardiology and Cardiac Surgery in collaboration with the Society of Pediatric Cardiology Training Program Directors.

Technological advances have likewise contributed to the course value. An online syllabus now makes it possible for presented slide material to be viewed in full-color full-page format. Practice examination Q&A exercises following each presentation are supported by audience-response system technology. Presentations are recorded to produce a “watch-it-again” option, available shortly after the course and a CM-accredited DVD version of the course released soon after the end of the course. An online option for those wishing to earn MOC credit was introduced in 2014.

Continuing advances in the specialty and expanding needs of our constituency have certainly contributed to course growth as well, especially in recent years as those who are already Board Certified prepare to meet re-certification requirements and practitioners strive to remain current in our ever-expanding field.

The past 42 years have been a rewarding journey for me and the many others who have contributed to the success of the course, as we have had the honor to come to know hundreds of fine specialists and interact with them over the span of their careers. Whether you are new to the “Specialty Review in Pediatric Cardiology Course” or a member of our distinguished alumni, we look forward to having you with us in Chicago this coming August 13-17.

For details on the upcoming 2018 offering, please visit the course website: http://pediatriccardiologycourse.com.

CCT

Planning Committee

Maria Serratto, MD, FAAP, FACC, FCCP
Course Director

Laurie R. Armsby, MD, FAAP, FSCAI
Course Co-Director

David W. Brown, MD, FAAP
Antonio G. Cabrera, MD, FAAP
Shaji C. Menon, MD, FAAP, FASE, FACC
Christina Ronai, MD, MEd, FAAP, FAAC

Invited Faculty

Christopher S. Almond, MD, MPH
Laurie R. Armsby, MD, FAAP, FSCAI
David W. Brown, MD, FAAP
Antonio G. Cabrera, MD, FAAP
John M. Costello, MD, MPH, FAAP
Lisa C.A. D’Alessandro, MD, FAAP, FRCPC
Jeffrey Darst, MD
Sarah D. de Ferranti, MD, MPH, FAAP, FAHA
Dunbar Ivy, MD, FAAP, FACC, FAHA
Amy N. McCammond, MD
Shaji C. Menon, MD, FAAP, FASE, FACC
Carlos M. Mery, MD, MPH, FAAP
Stephen Paridon, MD, FAAP, FACC
Andrew J Powell, MD, FACC
Christina Ronai, MD, MEd, FAAP, FAAC
Lloyd Y. Tani, MD
Anne Marie Valente, MD, FACC, FAHA, FASE
Paul M. Weinberg, MD, FAAP, FACC
Gary M. Weiner, MD, FAAP
Frank J. Zimmerman, MD

Maria Serratto, MD, FAAP, FACC, FCCP
Course Founder & Director
Professor of Pediatrics, Division of Pediatric Cardiology
University of Illinois at Chicago College of Medicine
Children’s Hospital University of Illinois
Chicago, IL USA
MSerratt@UIC.EDU

Collaborate.. Educate.. Innovate.. Sustain
Educating, operating, and supporting pediatric cardiac care around the world
cardiac-alliance.org/volunteer  cardiac-alliance.org/donate

Novick Cardiac Alliance
Two-Year Feasibility Study Results Encouraging with Medtronic Harmony™ Transcatheter Pulmonary Valve

On April 26, 2018, Medtronic plc (NYSE: MDT) today announced two-year outcomes for the Harmony™ Transcatheter Pulmonary Valve (TPV) from its early feasibility study. Presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 41st Annual Scientific Sessions, data from 18 patients followed out to two years revealed the Harmony TPV showed solid valve function and no Paravalvular Leak (PVL).

"Following the one-year feasibility outcomes, we are encouraged to see the Harmony valve continues to show positive outcomes for patients two years post-implant," said Matthew J. Gillespie, MD, cardiologist at The Cardiac Center at Children’s Hospital of Philadelphia, who presented the data at the meeting. "We are optimistic that these early outcomes will be a strong indicator of the types of results that we might expect to see from our pivotal study, which is currently enrolling."

Designed to offer a treatment alternative for patients with Congenital Heart Disease (CHD), the Harmony TPV is being studied in CHD patients born with Right Ventricular Outflow Tract (RVOT) anomalies who undergo a surgical repair early in life. For these patients, who account for approximately 80% of CHD patients born with RVOT anomalies, the Harmony TPV provides a less invasive option to help restore normal valve function later in life.

Consistent with one-year outcomes presented at TCT16, patients enrolled in the Harmony TPV early feasibility study who have now been followed out to two years (N=18) continued to experience strong hemodynamics (blood flow), with 86.7% of patients having no trace pulmonary regurgitation (PR) at two years. Mean gradients were consistent and stable at two year follow-up, and there were no paravalvular leaks reported. Two patients experienced tissue growth within the stent frame and were treated successfully with a transcatheter valve-in-valve procedure with the Melody™ TPV.

"It’s important that these patients have access to a less invasive, non-surgical option, and the Harmony TPV is uniquely designed to adapt to a wide variety of patient anatomies," said Pieter Kappetein, MD, PhD, VP and Chief Medical Officer of the Structural Heart business, which is part of the Cardiac and Vascular Group at Medtronic. "Medtronic remains committed to Congenital Heart Disease, and we continue to look for ways to expand therapeutic options and improve outcomes for these patients, from their first surgeries as young children through their years as active, high-functioning adults."

The Harmony TPV is available for investigational use only. Harmony Pivotal IDE Study is treating up to 40 patients at approximately 15 sites in the U.S., Canada, and Japan. Medtronic has a long-standing commitment to Congenital Heart Disease and introduced the first transcatheter heart valve available anywhere in the world in 2006 – the Melody TPV – which has been implanted in more than 12,000 patients worldwide.

In collaboration with leading clinicians, researchers and scientists worldwide, Medtronic offers the broadest range of innovative medical technology for the interventional and surgical treatment of cardiovascular disease and cardiac arrhythmias. The company strives to offer products and services that deliver clinical and economic value to healthcare consumers and providers around the world.

Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 84,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries.

B.Braun Interventional Systems Launches Expanded CP Stent® Portfolio in Collaboration with NuMED, Inc.

B.Braun Interventional Systems Inc. (BIS) in collaboration with NuMED Inc., recently announced the Food and Drug Administration pre-market approval and U.S. commercial launch of an expanded size offering and new indication for the Cheatham-Platinum (CP) Stent portfolio.

The CP Stent became available in the U.S. market in 2016 for treatment of coarctation of the aorta with BIS entering into an exclusive U.S. distribution agreement with the manufacturer, NuMED Inc. Building upon the success of the CP Stent in the market, and in an effort to address unmet clinical needs, additional sizes and indications have been pursued.

The newly approved indication applies to the Covered and Covered Mounted CP Stent™ configurations for the treatment of right ventricle to pulmonary artery (right ventricular outflow tract, RVOT) conduit disruptions. These disruptions are identified during conduit pre-dilatation procedures performed in preparation for transcatheter pulmonary valve replacement (TPVR). The pivotal trial associated with this approval, PARCS (Pulmonary Artery Repair with Covered Stents), is publicly available on the ClinicalTrials.gov site for more details.

In addition to the new indication, this latest approval also includes additional sizes for the CP Stent portfolio. The expanded size offering includes CP Stent configurations expandable up to 30 mm in diameter.
Two Positions at Nationwide Children’s Hospital

Pediatric Electrophysiologist

The Heart Center at Nationwide Children’s Hospital in conjunction with The Ohio State University Department of Pediatrics in Columbus, Ohio seeks a board-certified/eligible, academic, and advance trained electrophysiologist at any professor level. This physician will join two full-time electrophysiologists. Preference will be given to experienced candidates who prefer a noninvasive electrophysiology focus although a mix of invasive and noninvasive responsibilities may be tailored to the individual. Additionally, the physician will perform a modest amount of general pediatric cardiology that includes night call and in-patient service. Leadership opportunities in clinic management, quality improvement, and education within our Heart Center are also available.

Candidates are encouraged to submit their curriculum vitae by email to Naomi Kertesz, MD, Director of Electrophysiology and Pacing Naomi.Kertesz@nationwidechildrens.org or to the Cardiology Section Chief Robert.Gajarski@nationwidechildrens.org.

General Pediatric Cardiologist

The Heart Center at Nationwide Children’s Hospital in conjunction with The Ohio State University Department of Pediatrics in Columbus, Ohio seeks an academic general pediatric cardiologist at any professorial level. Experienced candidates with three or more years of clinical practice are preferred. Clinical responsibilities include general outpatient cardiology, participation on our in-patient cardiology consultation service, and general cardiology night call. Other clinical interests may be explored. Leadership opportunities in clinic management and education are also available.

Candidates are encouraged to submit their curriculum vitae by email to the Cardiology Section Chief Robert.Gajarski@nationwidechildrens.org

The Heart Center is a dedicated hospital service-line that carries the mission of providing state-of-the-art, cost-effective care to our patients with congenital and acquired heart disease regardless of age. The Heart Center has >16,000 out-patient encounters per year including multiple specialty clinics (e.g. Fontan, muscular dystrophy, preventive care, cardiogenetic). The in-patient medical discharges are 1300/yr including 500 annual surgeries. The Heart Center has 37 cardiologists and four cardiothoracic surgeons, a dedicated 20-bed CTICU and 24-bed cardiac stepdown unit, and a dedicated administration team. Excellent services in cardiac intensive and stepdown care, catheterization and intervention, non-invasive imaging, electrophysiology, heart failure and heart/heart-lung/lung transplantation are on-site. The Heart Center has a robust adult congenital heart service. The population served includes the regional population, a large number of referred cases for advanced intervention and surgery, an extensive state-wide outpatient network (pediatric and adult congenital) and patients managed with regional partners including the newly formed Congenital Heart Collaborative. Our program is integrated with the Center for Cardiovascular Research. Nationwide Children’s Hospital is a 464 bed stand-alone children's hospital and is the pediatric teaching facility for The Ohio State University School of Medicine. Columbus is the state capital and the 14th most populous city in the US (metropolitan population just over 2 million). It is a diverse community with excellent schools, a thriving economy, and a vibrant arts/food scene.

The Ohio State University is an Equal Opportunity, Affirmative Action Employer. Women, minorities, veterans, and individuals with disabilities are encouraged to apply
and lengths up to 6 cm. All sizes and configurations of the Covered CP Stent are now approved for the treatment of both coarctation of the aorta and RVOT conduit disruptions, while the bare CP Stent configurations are only approved for the treatment of coarctation of the aorta.

“Over the first two years of U.S. commercial availability, the CP Stent has demonstrated an impressive record of clinical utility in some of the most challenging interventional cases. The recent portfolio expansion for larger diameters, longer lengths, and a new indication are significant developments for this critical product line,” said Peter Flosdorf, B. Braun Interventional Systems Engineering Manager. “We are proud to collaborate with NuMED to provide physicians with indispensable tools for the treatment of congenital heart defects.”

“The approval of the additional sizes and clinical applications for the CP Stent line is an exciting milestone for NuMED that further delivers on our commitment to improve patient care by bringing to market innovative solutions to unmet clinical needs within the structural heart community,” said Al Tower, President of NuMED, Inc. “We are pleased to continue our longstanding collaboration with the B. Braun Interventional Systems team to help us support the U.S. market for congenital heart interventions.”

B. Braun Interventional Systems offers interventional solutions designed with the patient in mind. Many of the products offered have been developed in response to the needs of physicians, technicians, and nurses. The company is committed to delivering safety, precision and convenience to interventional procedures. B. Braun Interventional Systems Inc. is part of the B. Braun Group of Companies in the U.S., which is headquartered in Bethlehem, PA, and includes B. Braun Medical Inc., Aesculap® and CAPS®.

Globally, the B. Braun Group of companies employs more than 61,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Interventional Systems Inc., visit www.bisusa.org/about-us.

Since 1982, NuMED has been developing, manufacturing and delivering innovative cardiovascular medical products for the smallest of patients to adults with heart defects.

Headquartered in Hopkinton, NY, NuMED’s mission is to improve the quality of patient care and the productivity of health care by developing and advocating less-invasive medical devices and procedures. They are committed to continually refining their existing products, and researching new technologies that can reduce risk, trauma, cost, procedure time and the need for aftercare. To learn more about NuMED, visit www.numedforchildren.com.

Terumo Aortic Announces European Launch of Relay®Pro THORACIC Stent Graft System at Charing Cross s 2018

Terumo Aortic announced the European limited market release of the RelayPro Thoracic Stent-Graft System at the 2018 Charing Cross Conference. RelayPro is a low profile, next generation device designed to expand the treatment of Thoracic Endovascular Aortic Repair (TEVAR) to patients with smaller access vessels. Utilizing the same stent design, material, and Dual Sheath Technology of the proven RelayPlus with a 3- to 4-Fr. reduction in outer profile, RelayPro delivers the accuracy, control and confidence of the RelayPlus without compromising device integrity and durability.

RelayPro offers physicians a wide range of diameters, lengths, tapers, and proximal configurations. Available in both Bare Stent and Non-Bare Stent (NBS) versions, RelayPro can be individualized to meet the specific anatomical needs of patients.

Mark Miles, Global VP of Marketing at Terumo Aortic, said: “By combining the proven stent design and material of RelayPlus with a lower outer profile, RelayPro enables percutaneous access to treat a larger patient population. This advancement not only expands patient applicability but will help improve access site complications and ultimately reduce the burden of rising global healthcare costs.”

RelayPro is currently enrolling in multiple trials in U.S. and Japan for treatment of Descending Thoracic Aortic Aneurysms, Acute Complicated Type B Thoracic Aortic Dissection, and Blunt Aortic Trauma.
Academic Pediatric Cardiologist - Director of Non-invasive Imaging

The Division of Pediatric Cardiology at Louisiana State University Health Sciences Center, at the Children’s Hospital of New Orleans, is seeking a Pediatric Cardiologist to serve as Clinical Director of Non-Invasive Imaging to join its growing program. The Heart Center faculty includes a team of 8 full-time pediatric cardiologists, including sub-specialty expertise in Pediatric and Fetal Imaging, Electrophysiology, Interventional Cardiology, and Adult Congenital Cardiology. Heart Center staff also include 3 CV Surgeons and 3 CICU MDs. The Heart Center is proud to be part of the only freestanding Children’s Hospital in New Orleans and Louisiana, and the top academic heart program in the state. Academic appointment will be at the rank of Assistant Professor, Associate Professor or Full Professor (non-tenure, clinical track), and will be determined by the candidate’s credentials and experience. The successful candidate must have demonstrated excellence in non-invasive imaging. Incumbent will be involved in developing and leading a comprehensive state-of-the-art Imaging Program at Children’s Hospital.

Position offers competitive benefits, and a compensation package commensurate with training and experience.

Children’s Hospital resides in New Orleans’ historic and vibrant uptown area. Our campus is currently undergoing a $300 million physical revitalization and transformation, and at the same time expanding new multispecialty outpatient campuses in the city and region. The Heart Center program provides services for patients throughout the state of Louisiana, including 260 CV surgeries, 275 cardiac catheterizations, 5000 ambulatory visits, and 5500 ECHOs annually. There is a dedicated 20 bed CICU with dedicated in-house attending coverage and a recently completed state of the art hybrid catheterization suite. The incoming Imaging Director would be given the responsibility of developing and organizing Imaging services and resources as the program transitions into the new Children’s clinical infrastructure.

New Orleans is one of the two largest cities in Louisiana and famous for its vast cultural, musical, culinary and outdoor resources and activities. The city offers its citizens a warm climate, matched with a warm and friendly regional atmosphere year-round. Interested and qualified candidates should apply to:

Qualifications
- MD or MD/PhD or equivalent
- BC in Pediatric Cardiology at start date
- Licensed to practice medicine in the State of Louisiana before start date

For questions about this position, please feel free to contact Dr. Ernest Siwik at esiwik@lsuhsc.edu

Applicant Instructions

Interested candidates should submit a cover letter, CV and list of references electronically: https://lsuh.sc/jobs/?id=2048

The LSUHSC School of Medicine in New Orleans encourages women and minority candidates to submit applications for this position. The School of Medicine does not participate in sponsoring faculty candidates for the Department of Health and Hospitals’ Conrad 30 Program.

LSU Health-NO is an Equal Opportunity Employer for females, minorities, individuals with disabilities and protected veterans.

Terumo has combined Bolton Medical and Vascutek to power a dedicated approach focused on aortic innovation. With locations in Glasgow, Scotland and Sunrise, Florida, the integrated company offers advanced technologies such as surgical grafts, hybrid grafts and catheter-based stent graft systems to meet the unique needs of each patient and transform the treatment of aortic disease.

WAVE TeleTrend and AlarmView in Epic App Orchard:
Excel Medical WAVE TeleTrend and AlarmView Offer Predictive Analytics Apps to Epic Users

Excel Medical of Jupiter, FL, announced on May 8th that WAVE™, the first-ever FDA-cleared patient surveillance and predictive algorithm platform, is now available through its AlarmView™ and TeleTrend™ applications in Epic’s App Orchard. Both apps allow hospital systems to make predictive analytics an actionable process.

“Being in App Orchard is not only a game changer for Excel—by integrating our predictive analytics into Epic—but more importantly, it opens the doors to improved patient surveillance for clinical care teams,” says Mary Baum, Chief Strategy Officer at Excel Medical. “WAVE, via TeleTrend and AlarmView, brings 95% positive predictive value into the early detection of at-risk patient deterioration.”

Since WAVE became the world’s first patient surveillance and predictive algorithm platform to receive FDA clearance in January 2018, Excel Medical has been working to maximize its impact through new relationships, organizational augmentation, and a renewed dedication to the company’s mission—to eliminate unexpected deaths in hospitals.

This goal, once far-reaching, has now moved to “accessible” by tapping into Epic’s open, standards-based interoperability platform, and at the same time, by leveraging the widespread data generating infrastructure (BedMasterEx™ and BedComm™ solutions) that Excel already has installed in so many hospital sites.

“To be effective at predicting patient deterioration and catastrophic events it is vital that we have close working
relationships with all of our hospital EMR partners,” says Lance Burton, President of Excel Medical. “In working with Epic, we have been very pleased with their responsiveness and the simplicity of the resulting user interface. Obviously, we believe there is a new WAVE in healthcare and we are excited to be part of it.”


Excel Medical’s technologies were designed with one goal in mind—to eradicate unexpected deaths in hospitals. There are more than 400,000 unexpected deaths in U.S. hospitals annually making it the nation’s third-leading cause of death—behind heart disease and cancer. Excel Medical’s “True North” is to make predictive analytics an actionable process, “predicting the preventable™”, making it possible to achieve zero unexpected hospital deaths. Excel Medical was founded in 1995, and its products/services are used by more than 80% of the top academic medical centers and children’s hospitals in the United States. Excel Medical has multiple high-profile partners including IBM Watson, OBS Medical and EPIC. It is a privately-held company headquartered in Jupiter, FL, with customers throughout North America, Europe, Australia and Asia. For more information: www.Excel-Medical.com.

CONGENITAL CARDIOLOGY TODAY

CALL FOR CASES AND OTHER ORIGINAL ARTICLES

Do you have interesting research results, observations, human interest stories, reports of meetings, etc. to share?

Submit your manuscript to: RichardK@CCT.bz

Are You in the Field of Neonatology?

If you answered “yes,” you may qualify for a Free subscription to: NEONATOLOGY TODAY.

To subscribe, send an email to: Subs@Neonate.Biz, and include your name and title, organization, mailing address, fax and phone numbers, email, current position and academic titles, as well as fellowship status in professional societies. If your organization has a website, please include that as well. We will confirm your subscription by email.

www.NeonatologyToday.net
The Heart Institute at the
CHILDREN’S HOSPITAL OF PITTSBURGH OF UPMC
Is EXPANDING!

With a strategic plan for growth and expansion, the Division of Cardiology within the Heart Institute of the Children’s Hospital of Pittsburgh of UPMC / University of Pittsburgh School of Medicine is recruiting additional faculty positions.

TWO IMAGING FACULTY WITH EXPERTISE IN CARDIAC MR or FETAL ECHOCARDIOGRAPHY

We are recruiting for two imagers with a focus on FETAL echocardiography or cardiac MRI. Completion of a 4th year imaging fellowship plus skill and independence in transesophageal echocardiography is a requirement. Faculty will join an outstanding imaging team: Including eleven echocardiographers, 16 pediatric sonographers in a highly productive echo lab – with over 18,000 echocardiograms, including over 1200 fetal echo’s and 550 TEE’s.

Echocardiography program covers Children’s Hospital, Magee Women’s hospital and multiple outreach sites and a robust tele-echo program. The cMR pediatric cardiology position is to join a strong partnership between cardiology and radiology. CHP has a state-of-the-art MRI facility with a new 3D lab and plans for growth with an additional cardiac MRI scanner. Further collaboration with the adult cardiology program for ACHD cMR program is anticipated. Candidates must be board-eligible/certified in pediatric cardiology.

The Heart Institute provides comprehensive pediatric and adult congenital cardiovascular services to the tri-state region and consists of 25 pediatric cardiologists, 4 pediatric cardiothoracic surgeons, 5 pediatric cardiac intensivists and 9 cardiology fellows along with 12 physician extenders and a staff of over 100. The Heart institute is currently ranked 12th in the US News and World report ranking for pediatric cardiac programs. The Cardiac surgical program is one of the top in the country, with a 3-star rating from Society of Thoracic Surgery (STS) in the most recent survey.

Children’s Hospital of Pittsburgh of UPMC has been named to U.S. News & World Report’s 2015-16 Honor Roll of Best Children’s Hospitals, one of only 10 hospitals in the nation to earn this distinction. Consistently voted one of America’s most livable cities, Pittsburgh is a great place for young adults and families alike.

The positions come with a competitive salary and faculty appointment commensurate with experience and qualifications at the University of Pittsburgh School of Medicine. The University of Pittsburgh is an Equal Opportunity/Affirmative Action Employer. Interested individuals should forward letter of intent, curriculum vitae and three (3) letters of references. Informal inquiries are also encouraged.

Contact information:

Jacqueline Kreutzer, MD, FSCAI, FACC.
Chief, Division of Pediatric Cardiology
Children’s Hospital of Pittsburgh of UPMC
4401 Penn Avenue
Pittsburgh, PA 15224
Telephone: 412-692-6903
E-mail: Jacqueline.kreutzer@chp.edu

The University of Pittsburgh is an Affirmative Action/Equal Opportunity Employer and values equality of opportunity, human dignity and diversity. EEO/AA/M/F/Vets/Disabled
NIT-OCCLUD® Coil System
for PDA Closure

Designed For the Safe and Atraumatic Occlusion of the Congenital Heart Defect PDA (Patent Ductus Arteriosus)

INDICATIONS FOR USE:
The Nit-Occlud® PDA coil is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter less than 4mm.

NIT-OCCLUD BRIEF STATEMENT:
Do not implant the Nit-Occlud PDA into patients who have endocarditis, endarteritis, active infection, pulmonary hypertension (calculated PVR greater than 5 Wood Units), thrombus in a blood vessel through which access to the PDA must be obtained, thrombus in the vicinity of the implantation site at the time of the implantation or patients with a body weight < 11 lbs. (5kg). An angiogram must be performed prior to implantation for measuring length and diameter of the PDA. Only the pfm medical implantation delivery catheter should be used to implant the device. Administration of 50 units of heparin per kg bodyweight should be injected after femoral sheaths are placed. Antibiotics should be given before (1 dose) and after implantation (2 doses) to prevent infection during the implant procedure. Do not implant the Nit-Occlud PDA in an MR environment. Do not pull the Nit-Occlud coil through heart valves or ventricular chambers. Contrast media should not be injected through the implantation catheter. The catheter must not be connected to high pressure injectors. Patients may have an allergic response to this device due to small amounts of nickel that has been shown to be released from the device in very small amounts. If the patient experiences allergic symptoms, such as difficulty in breathing or swelling of the face or throat, he/she should be instructed to seek medical assistance immediately. Antibiotic prophylaxis should be performed to prevent infective endocarditis during first 6 months after coil implantation. Potential Adverse Events: Air embolism, Allergic reaction to drug/contrast, Apnea, Arrhythmia requiring medical treatment or pacing, Arteriovenous fistula, Bacterial endocarditis, Blood loss requiring transfusion, Chest pain, Damage to the tricuspid or pulmonary valves, Death, Embolization of the occluder, requiring percutaneous or surgical intervention, Endarteritis, False aneurysm of the femoral artery, Fever, Headache/Migraine, Heart failure, Hemolysis after implantation of the occluder, Hypertension, Hypotension or shock, Infection, Myocardial infarction, Occluder fracture or damage, Perforation of the heart or blood vessels, Stenosis of the left pulmonary artery or descending thoracic aorta, Stroke/TIA, Thromboembolism (cerebral or pulmonary), Vasculitis Regurgitation, Vessel damage at the site of groin puncture (loss of pulse, hematoma etc.).

Nit-Occlud is a registered trademark of pfm medical Inc.

Rx only CV9064 - 5/17 ©2017 B. Braun Interventional Systems Inc.

Distributed by:
B. Braun Interventional Systems Inc.
824 Twelfth Avenue  |  Bethlehem, PA 18018  |  USA
Tel 877 836 2228 |  Fax 610 849 1334  |  www.bisusa.org